Latest Fundraising News

Pacific Current Group reports a 3.1% decline in funds under management in Australian dollars for Q4 FY25, driven largely by currency appreciation despite modest inflows and performance gains in native currencies.

Entertainment Rewards Ltd reports a 6.1% revenue increase in Q4 FY25, driven by growth in key programs and a new $2.5 million loan facility, while narrowing its operating loss.

ASF Group Limited reported a stable cash position of $1.3 million as of June 2025, accepted a takeover offer for its stake in Rey Resources, and continued to develop its innovative technology and biotech investments.

Bannerman Energy reported a robust $80 million cash inflow from financing in Q2 2025, offsetting significant exploration expenditures and maintaining a strong cash position.

Kaiser Reef has completed a transformative acquisition of the Henty Gold Mine, backed by a $20.9 million capital raise, positioning the company for significant growth in Tasmania and Victoria.

Peninsula Energy has completed a major reset of its uranium offtake contracts, terminating five of six agreements with a $6.6 million payout, while advancing commissioning of its Central Processing Plant toward first yellowcake production in Q3 2025.

Zenith Minerals has secured final Turkish regulatory approval for the sale of its Kavaklitepe Gold Project stake, unlocking approximately A$830,000 in cash proceeds. This milestone paves the way for the company to accelerate exploration at its core Australian gold assets.

Navigator Global Investments (NGI) reported a 7% rise in total firm-level assets under management (AUM) to USD 86 billion in the June 2025 quarter, driven by strong performance from Lighthouse Partners and strategic private markets.

Orion Minerals has raised approximately A$5.8 million through a share placement and loan conversions, while launching a Share Purchase Plan targeting an additional A$4 million to fund key copper projects.

Firebrick Pharma has raised $0.2 million in a placement well below its $1.6 million target, prompting a review of its expansion and product development plans for Nasodine.

Biotron Limited has completed the initial safety phase of its lead Hepatitis B drug in animal studies, paving the way for efficacy testing in two distinct mouse models. This milestone marks a significant step forward in the company’s antiviral drug development program.

Investigator Resources has secured $4.3 million through a share placement to fund expanded drilling programs and advance its Paris Silver Project DFS in South Australia.